T&R Biofab said Wednesday that it signed a strategic joint development agreement with Johnson & Johnson Innovation to develop the 3D bio-printing scaffold technology.

According to T&R Biofab, the contract’s purpose is to develop an implantable product in the body based on diverse biomaterials and biosynthetic polymer materials utilizing T&R’s 3D bio-printing technology, the company excels. The development will be based on T&R Biofab’s platform.

The company said its platform technology based on 3D bio-printing technology meets diverse mechanical strength standards and maintains biocompatible safety while overcoming the weakness of materials used in the organizational reconstruction.

“The agreement is significant as the result of expanded cooperation with Johnson & Johnson Innovation,” T&R Biofab CEO Yoon Won-soo said. “It is the second collaboration between the two companies followed by a joint research and development agreement in 2020.”